Optimize Dermatology Denial Management for Biologics and Mohs Surgery

Effective **dermatology denial management** is critical for practices navigating complex prior authorization landscapes for high-cost biologics and specialized procedures like Mohs surgery. Klivira streamlines this workflow, ensuring timely appeals and reduced administrative burden.

Denials in dermatology frequently stem from issues like step therapy non-compliance for biologics, insufficient documentation of disease severity, or Mohs Appropriate Use Criteria mismatches. Manually parsing X12 835 and 277 denial codes, assembling comprehensive appeal packets, and tracking timely filing windows consumes significant staff resources and risks lost revenue. Klivira's platform provides an automated solution to these challenges.

Common Denial Triggers in Dermatology

Dermatology practices frequently encounter prior authorization denials for high-cost biologics such as Dupixent, Cosentyx, Tremfya, and Skyrizi, as well as for Mohs micrographic surgery. Common denial reasons include failure to document prior topical or systemic therapy trials, biosimilar substitution requirements for TNF inhibitors, Mohs Appropriate Use Criteria (AUC) mismatches, and missing documentation of disease severity scores like PASI or EASI.

The Impact of Manual Denial Workflows on Dermatology RCM

Without automation, dermatology revenue cycle teams face significant challenges in denial management. Manual parsing of X12 CARC/RARC codes from 835s or 277s can lead to miscategorized denial reasons and incorrect routing. This increases the risk of timely-filing breaches for appeals, results in lost-to-follow-up appeals, and often leads to write-offs for claims that could have been successfully appealed, directly impacting practice revenue.

Klivira's Automated Denial Management for Dermatology

Klivira's platform automates the end-to-end denial management lifecycle, specifically addressing the complexities of dermatology prior authorizations. We ingest denials from all channels, including X12 835, X12 277, and Da Vinci PAS ClaimResponse, applying a uniform denial-reason taxonomy across X12 codes and payer-specific variations. This enables auto-routing of denials to the appropriate workflow, whether it's claim correction, appeal, or peer-to-peer review.

Streamlining Appeals for Biologics and Specialty Drugs

**AAD Guideline-Aware Logic:** Automated validation against AAD Clinical Guidelines for step therapy compliance for biologics (e.g., psoriasis, atopic dermatitis).
**Comprehensive Documentation Assembly:** Automated discovery and assembly of supporting clinical documentation from the EMR via FHIR, including PASI/EASI/BSA scores, prior therapy history, and screening results (e.g., TB, hepatitis).
**Periodic Re-authorization Workflow:** Proactive tracking and management of re-authorization cycles for chronic biologic treatments, ensuring continuous coverage.
**Medical vs. Pharmacy Benefit Routing:** Intelligent routing logic to address denials related to self-injection at home versus clinic infusion, optimizing benefit utilization.

Enhancing Mohs Surgery Denial Resolution

**AUC Validation:** Automated verification against Mohs Appropriate Use Criteria (AUC) for site, tumor type, and prior treatment history.
**Targeted Appeal Packet Generation:** Assembly of appeal packets specifically addressing Mohs AUC mismatches, ensuring all required documentation is included to justify medical necessity.
**Payer Policy Alignment:** Adapting appeal strategies to varying payer policies for Mohs micrographic surgery indications and documentation requirements.

Feedback Loop for Upstream Prior Authorization Accuracy

Beyond resolving current denials, Klivira's platform provides critical insights by surfacing denial-reason patterns by payer, service line, and provider. This feedback loop informs and improves upstream prior authorization submission accuracy for dermatology services, proactively reducing future denial rates and enhancing overall revenue cycle performance. This data-driven approach transforms reactive denial management into a strategic asset.

Frequently asked questions

How does Klivira handle step therapy denials for dermatology biologics?

Klivira's platform incorporates AAD Clinical Guideline-aware logic to validate and document compliance with payer step therapy requirements for biologics. It automatically identifies missing documentation of prior topical or conventional systemic therapy trials (e.g., methotrexate), facilitating the assembly of a complete appeal packet.

What specific denial codes does Klivira automate for dermatology practices?

Klivira normalizes X12 CARC and RARC codes received via 835 and 277 transactions, as well as payer-specific local denial variations, into a uniform taxonomy. This allows for automated parsing and routing of common dermatology denial reasons, such as those related to medical necessity, documentation deficiencies, or eligibility.

Can Klivira help with Mohs surgery denials related to Appropriate Use Criteria?

Yes, Klivira's system includes logic for Mohs Appropriate Use Criteria (AUC) validation. For denials related to site, tumor type, or prior treatment, the platform assists in assembling appeal packets with the specific clinical documentation required to demonstrate conformance with AUC guidelines, improving the likelihood of a successful appeal.

How does Klivira integrate with our EMR to gather documentation for appeals?

Klivira leverages SMART on FHIR standards to securely access and pull relevant clinical documentation from your EMR. This includes patient notes, lab results, imaging reports, and updated problem lists, which are crucial for building robust appeal packets for clinical-necessity denials in dermatology.

Does Klivira track re-authorization cycles for chronic dermatology treatments?

Yes, Klivira supports the management of periodic re-authorization workflows common for chronic biologic treatments in dermatology, typically on 6 or 12-month cycles. The platform tracks these cycles and proactively prompts for necessary documentation and re-submission, preventing service interruptions due to lapsed authorizations.